

An Overview of the Medical Device Industry

Sujan Rajbhandary, CFA

Mercer Capital sujanr@mercercapital.com 901.685.2120

September 2016



Medical Device Industry Services

Mercer Capital provides valuation services to start ups, larger public and private companies, and private equity and venture capital funds.

Mercer Capital's expertise in the medical device industry spans the following segments:

- Cardiovascular
- · Orthopedic & Spinal
- Biologics
- Dental
- Diagnostics Equipment

Our services include:

- Purchase price allocations
- Impairment testing
- Portfolio valuation for LP reporting
- Transaction and valuation advisory
- Equity compensation valuation for 409a compliance

Contact Us Medical Device Professionals



Sujan Rajbhandary, CFA sujanr@mercercapital.com 901.685.2120



Travis W. Harms, CFA, CPA/ABV harmst@mercercapital.com 901.685.2120

MERCER CAPITAL
Memphis | Dallas | Nashville
www.mercercapital.com




Lifecycle: Stages and Players



Lifecycle

Of Technology / Product / Platform




Timeline shown is demonstrative, not definitive



Lifecycle

Of Technology / Product / Platform



Timeline shown is demonstrative, not definitive




Follow the Money: Price Feedback Loop?



Follow the Money

Purchasing Decision Largely Disconnected from Price






Valuation is a Function of: Cash Flow, Growth, and Risk



Demand – Demographics is Destiny

US Population Distribution by Age Group




Data source: US Census Bureau



Demand – Demographics is Destiny, Too

US Adult Obesity Rates




Data source: Centers for Disease Control and Prevention; Trust for America's Health, Robert Wood Johnson Foundation



Those who Pay, (Hope to) Get a Say

Payor Mix - Health Consumption Expenditures



Source: National Health Expenditures Accounts, Centers for Medicare & Medicaid Services [Amounts in current dollars]



People the World Over are Getting Richer – and Spending More on Healthcare

	% of GDP	Per Capita	Growth, Ann.	2012 Payor Mix		
	2012	2012	2005-12	Govt	Private	
Region*						
United States	18%	\$8,895	4%	46%	54%	
Africa	6%	\$147	7%	52%	48%	
Americas ex US	7%	\$733	10%	58%	42%	
Eastern Mediterranean	5%	\$525	9%	53%	47%	
Europe	8%	\$2,349	5%	67%	33%	
South-East Asia	4%	\$129	11%	50%	50%	
West Pacific	7%	\$982	8%	72%	28%	
Select Countries	_					
Australia	9%	\$6,014	10%	66%	34%	
Brazil	9%	\$1,056	15%	46%	54%	
Canada	11%	\$5,741	8%	70%	30%	
China	5%	\$322	22%	56%	44%	
France	12%	\$4,690	3%	77%	23%	
Germany	11%	\$4,683	4%	76%	24%	
India	4%	\$61	10%	33%	67%	
Israel	8%	\$2,289	6%	62%	38%	
Japan	10%	\$4,752	7%	82%	18%	
Mexico	6%	\$618	4%	52%	48%	
Norway	9%	\$9,055	5%	85%	15%	
Republic of Korea	8%	\$1,703	8%	54%	46%	
Russian Federation	6%	\$887	18%	61%	39%	
Singapore	5%	\$2,426	13%	38%	62%	
United Kingdom	9%	\$3,647	2%	83%	17%	

^{*}Expenditures (US Dollars) and share statistics shown are averages for the regions. Growth rates are medians for the regions

Source: Global Health Expenditures Database, World Health Organization



Regulation Cuts Both Ways

On the one hand


The process of selling new products to regulators and insurers is long and arduous

On the other hand

These difficulties create substantial barriers to entry



Is Risk/Reward Getting Less Favorable for Early Investors?





Industry Summary: Features, Snapshot, and M&A Trends



Industry Features

High profitability

Purchasing decisions disconnected from prices

Substantial barriers to entry

Sustained growth

Demographic tailwind

Income, wealth growth outstripping more basic needs

Continual technological advancement

Virtuous cycle re: growth and profitability



Industry Snapshot

Public Medical Device Companies // Select Operating Metrics

	Gross Margin		EBITDA Margin		Operating Margin		R&D / Revenue	
Segment	Q2 2016	Q1 2016	Q2 2016	Q1 2016	Q2 2016	Q1 2016	Q2 2016	Q1 2016
Large, Diversified	66.7%	66.0%	26.7%	26.3%	14.0%	13.6%	7.2%	7.2%
IVD & Life Sciences	55.0%	55.3%	15.0%	14.6%	10.3%	10.0%	9.1%	9.2%
Cardiovascular	66.1%	66.3%	18.8%	17.6%	8.4%	7.4%	12.4%	12.3%
Ortho, Implants & Prosthetics	69.5%	69.3%	17.3%	17.2%	8.2%	8.0%	7.0%	7.0%
Other	53.3%	53.6%	5.8%	4.4%	-1.0%	-0.9%	8.1%	8.2%
All Companies	58.1%	57.8%	16.3%	15.7%	8.2%	8.0%	7.9%	7.9%

	Historical Rev Growth		LT Fwd Op Earn Grwth		Debt / EV		Debt / EBITDA	
Segment	Quarterly	Annual	Q2 2016	Q1 2016	Q2 2016	Q1 2016	Q2 2016	Q1 2016
Large, Diversified	1.0%	2.5%	11.2%	11.4%	14.8%	18.4%	2.6	2.7
IVD & Life Sciences	2.1%	2.7%	12.5%	14.0%	5.5%	4.9%	1.5	1.4
Cardiovascular	2.7%	5.0%	17.5%	16.5%	9.1%	10.6%	1.0	0.8
Ortho, Implants & Prosthetics	1.9%	5.6%	14.1%	14.3%	20.3%	23.2%	2.7	2.7
Other	2.5%	5.3%	14.0%	13.1%	8.0%	6.2%	0.5	0.4
All Companies	2.4%	4.5%	13.6%	13.4%	10.4%	10.5%	1.3	1.4

Median measures for each group. | Data Source: Bloomberg; Mercer Capital Analysis



Industry Trends

M&A Motivations

Consolidation

- Efficient sales channels relatively small number of physicians responsible for much/all buying decisions
- Concentration of product families tends to give rise to complementary portfolios
- Potential for operating leverage specialized selling process, low capital intensity, thin layer of administrative support

Acquisition of new technology

Direct selling vs. using stocking distributors



About Mercer Capital

Mercer Capital is a national business valuation and financial advisory firm.

We offer a broad range of services, including corporate valuation, financial institution valuation, financial reporting valuation, gift and estate tax valuation, M&A advisory, fairness opinions, ESOP and ERISA valuation services, and litigation and expert testimony consulting.

We have provided thousands of valuation opinions for corporations of all sizes in a wide variety of industries. Our valuation opinions are well-reasoned and thoroughly documented, providing critical support for any potential engagement.

Our work has been reviewed and accepted by the major agencies of the federal government charged with regulating business transactions, as well as the largest accounting and law firms in the nation in connection with engagements involving their clients.

For over thirty years, Mercer Capital has been bringing uncommon professionalism, intellectual rigor, technical expertise, and superior client service to a broad range of public and private companies and financial institutions located throughout the world. Feel confident in our experience and expertise.

Mercer Capital

Memphis | Dallas | Nashville 800.769.0967 // www.mercercapital.com



Mercer Capital's Core Services

Valuation & Financial Opinions

- Litigation Related Expert Witness Opinions
- Succession & Shareholder Planning
- Valuations for Corporate Tax Planning
- Valuations for Gift & Estate Tax Planning
- Fairness Opinions
- ESOP & ERISA Advisory Services
- Bankruptcy Related Valuation Services
- Valuations for Buy-Sell Agreements

Transaction Advisory Services

- M&A and investment banking services
- Fairness Opinions
- Buy-sell Agreements & Private Company Transactions
- Strategic Assessments

Litigation Support Services

- Statutory Fair Value
- Business Damages & Lost Profits
- Valuation, Labor & Contract Disputes
- Family Law & Divorce
- Tax Related Controversies
- Corporate Restructuring & Dissolution
- Initial Consultation & Analysis
- Testimony & Trial Support

Financial Reporting Valuation Services

- Purchase Price Allocation Services
- Impairment Testing Services
- Portfolio Valuation Services
- Equity-Based Compensation Valuation Services